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Atopicdermatitisoftheheadandneck(HNAD)isrecognizedasaseparatecondition.Malassezia,thepredominantskinmicrobiota
fungus,isconsideredtoexacerbateatopicdermatitis(AD),especiallyHNAD.Inthepresentstudy,weinvestigatedtherelationships
between the levels of speciﬁc IgE antibodies, colonization frequency of eight predominant Malassezia species, and clinical severity
in 61 patients with HNAD (26 mild, 24 moderate, and 11 severe cases). As clinical severity increased, the levels of speciﬁc IgE
antibodies against eight Malassezia species also increased. Species diversity of the Malassezia microbiota in scale samples from
patients was analyzed by nested PCR using species-speciﬁc primers. The clinical severity of HNAD was correlated with the total
level of speciﬁc IgE antibodies against Malassezia species and the number of Malassezia species detected.
1.Introduction
Atopic dermatitis (AD), which is characterized by dermatitis
with pruritus, is a chronic disease that exhibits repeated peri-
ods of remission and deterioration. This disease is caused by
hypersensitivity to dry skin, a predisposing atopic factor in
which IgE antibodies related to the allergy are readily pro-
duced,andvariousenvironmentalfactors.NumerousIgE-in-
ducing allergens play a role in the pathogenesis of AD. In
fact, speciﬁc IgE antibodies against environmental allergens
such as mites and various food allergens are detectable in the
sera of patients with AD. Since the human body is covered
with an enormous number of microorganisms of a pletho-
ra of types [1], some may exacerbate the symptoms of AD.
Staphylococcus aureus is an exacerbating factor in AD, and
staphylococcal superantigen-speciﬁc IgE is found in the se-
rum of patients with AD, but not healthy individuals [2, 3].
Normally, S. aureus does not colonize healthy skin. The skin
pH of patients with AD is neutral while that of healthy indi-
viduals is weakly acidic, and S. aureus does not grow well on
healthy skin because it prefers a neutral pH.
Withrespecttoskinfungi,approximately50speciescolo-
nize the skin of patients with AD [4], although the predom-
inant fungus on the skin is the lipophilic yeast Malassezia.
These microorganisms colonize sebum-rich areas such as
the head, face, and neck rather than the limbs or trunk be-
cause Malassezia requires lipids for growth. During the last
two decades, Malassezia has been considered to be an exacer-
bating factor in AD because anti-Malassezia-speciﬁc IgE is
present in the serum of patients with AD, but not healthy in-
dividuals [5–7]. In addition, clinical investigations with an-
tifungal agents (ketoconazole or itraconazole) showed im-
provements in AD symptoms, particularly atopic dermatitis
of the head and neck (HNAD) [8–12].2 Journal of Allergy
The presence of anti-Malassezia IgE has been demon-
strated in patients with HNAD [7, 13–15]. The detection fre-
quencyofanti-Malassezia-speciﬁcIgEinserumwashigherin
patients with HNAD than in those without. Bayrou et al. [7]
found IgE against Malassezia antigen in 100% of 106 patients
with HANAD, but in only 28% of 25 patients who had AD
withoutheadandneckinvolvement.Asigniﬁcantcorrelation
was also observed between the level of Malassezia-speciﬁc
IgE and clinical severity criteria, as reﬂected by the SCORAD
index.
Currently,14speciesarerecognizedwithinthegenusMa-
lassezia. Of them, both M. globosa and M. restricta were de-
tected in all scale samples of patients with AD when the Ma-
lasseziamicrobiotawasanalyzedbymolecular-basedculture-
independent methods [16]. The colonization level of M. re-
stricta was approximately 1.6 times greater than that of M.
globosa [17]. M. sympodialis was the third most predominant
species, with a detection rate of 58%. Other species, such as
M. dermatitis, M. furfur, M. obtusa,o rM. slooﬃae,w e r ed e -
tected in less than 30% of the cases.
In this study, we investigated the relationships between
speciﬁc IgE and the colonization frequency of the eight most
predominant Malassezia species and clinical severity levels
in patients with HNAD to determine the factors that were
correlated with clinical severity.
2. Methods
2.1. Subjects. Outpatients with HNAD (n = 61) at Toky-
o Medical University Hospital were enrolled. The study in-
volved patients comprising 26 mild (17 men and 9 women;
mean age 34.7 ± 10.5 years; range, 20–63), 24 moderate (16
m e na n d8w o m e n ;m e a na g e3 3 . 2± 9.7 years; range, 20–64),
and 11 severe (7 men and 4 women; mean age 32.7 ± 10.4
years;range21–51)cases.ADwasdiagnosedaccordingtothe
criteria of Haniﬁn and Rajka [18]. The study protocol was
approved by the Institutional Review Board, and informed
consent was obtained from all subjects.
2.2. Determination of Anti-Malassezia IgE Levels. Antigens
from each of eight Malassezia species were prepared (M.
dermatitis JCM 11469, M. furfur CBS 1878, M. globosa CBS
7966,M.japonicaCBS9432,M.obtusaCBS7876,M.restricta
CBS 7877, M. sympodialis CBS 7222, and M. slooﬃae CBS
7956) according to the method of Kato et al. [19]. IgE levels
against these antigens were determined using the AlaSTAT
microplate system (Diagnostic Products Corporation, Los
Angeles,CA,USA)withslightmodiﬁcationsaccordingtothe
method of Kato et al. [19]. Brieﬂy, the wells of a microtiter
plate were coated with 100µLo fe a c hMalassezia antigen in
phosphate-buﬀered saline (PBS). Serum (50µL) was then
added, followed by peroxidase-labeled anti-IgE antibodies.
After adding TMB (3,3 ,5,5 -tetramethylbenzidine dissolved
in hydrogen peroxide) substrate solution, the absorbance at
650nM was measured at 1s intervals for 5min. IgE levels
(units/mL) in the samples were calculated using a standard
curve, and IgE levels greater than 0.35U/mL were deﬁned as
a positive reaction.
2.3. Analysis of Malassezia Species Diversity. Scale samples
wereobtainedfromlesionsbystrippingwithOpSite,whichis
atransparentdressing(Smith&Nephew,Hull,UK),andMa-
lasseziaDNAwasextracteddirectlyfromthedressingaccord-
ing to the method of Sugita et al. [20]. Brieﬂy, the collected
dressing was placed in 1mL of lysing solution (100mM Tris–
HCl (pH 8.0), 30mM EDTA (pH 8.0), 0.5% sodium do-
decyl sulfate) and incubated at 100◦C for 15min. After de-
proteinization, DNA was precipitated with ethanol and Eth-
achinmate (Nippon Gene, Toyama, Japan). The DNA pellet
was resuspended in 30µLo fT Eb u ﬀer (10mM Tris–HCl
(pH 8.0), 1mM EDTA (pH 8.0)) and stored at −20◦C until
required. The Malassezia species diversity was investigated
using nested PCR with species-speciﬁc primers, following
the method of Sugita et al. [20] and Morishita et al. [21].
Brieﬂy, the Malassezia internal transcribed spacer or inter-
genic spacer region of the rRNA gene was ampliﬁed by PCR
with Malassezia universal primers. The product of this ﬁrst
ampliﬁcation (1µL) was used in the nested PCR step with
species-speciﬁc primers.
3. Results
3.1. Anti-Malassezia-Speciﬁc IgE Production. Malassezia-
speciﬁc IgE antibody levels against eight species in each
clinical severity group (mild, moderate, and severe) are
shown in Table 1. As clinical severity increased, IgE antibody
levels against all eight Malassezia species were also increased.
In patients with mild AD, the level of speciﬁc IgE against
M. restricta was the highest (1.13 ± 2.50U/mL), followed
by M. dermatitis (0.74 ± 1.56U/mL). Speciﬁc IgE for these
two species was also present at high levels in patients with
moderate AD (7.78 ± 8.84U/mL for M. restricta and 6.13
± 8.09U/mL for M. dermatitis). In severe patients, with the
exceptions of M. slooﬃae and M. obtusa, IgE antibody levels
againsttheremainingsixMalasseziaspecieswereeachgreater
than 15U/mL.
The detection frequencies of speciﬁc IgE antibody are
also shown in Table 1; greater than 0.35 U/mL was deﬁned
as a positive reaction. The detection frequency was also cor-
relatedwiththeseverityofsymptoms.SpeciﬁcIgEantibodies
against M. restricta and M. dermatitis were detected in 42.3%
of mild AD cases. Speciﬁc IgE antibodies against six Ma-
lassezia species, with the exceptions of M. slooﬃae and M.
obtusa, were detected in greater than 70% of moderate AD
cases. Speciﬁc IgE antibodies against all eight Malassezia spe-
cies were detected in more than 80% of severe cases.
3.2. Malassezia Skin Colonization Frequency. Malassezia
DNA in scale samples was detected by nested PCR using spe-
cies-speciﬁc primers. The colonization frequencies of eight
Malassezia species among the three clinical severity groups
were similar (Table 1). Also, these frequencies were similar
to those of eight Malassezia in healthy subjects. Both M. re-
stricta and M. globosa were detected in all samples. The third
most predominant species was M. sympodialis (detected in
54.5–61.5%).Theremainingﬁvespeciesweredetectedinless
than 40% of the cases. A total of two to seven Malassezia
speciesweredetectedfromeachpatient.TheaveragenumberJournal of Allergy 3
Table 1: Level and detection frequency of speciﬁc IgE antibody and colonization frequency of Malassezia species.
Species Speciﬁc IgE antibody value (IU/mL)a Detection frequency (%) of
speciﬁc IgE antibody
Colonization frequency (%) of
Malassezia species
Mild Moderate Severe Mild Moderate Severe Mild Moderate Severe HSb
M. restricta 1.13 ±2.50 7.78 ±8.84 22.74±27.52 42.3 87.5 100 100 100 100 100
M. globosa 0.41 ±0.65 3.24 ±2.74 16.99±13.24 34.6 83.3 100 100 100 100 100
M. sympodialis 0.37 ±0.45 4.46 ±4.74 20.74±16.52 30.8 83.3 100 61.5 58.3 54.5 36.7
M. dermatitis 0.74 ±1.56 6.13 ±8.09 34.47 ±30.89 42.3 79.2 100 38.5 37.5 27.3 30.0
M. japonica 0.26 ±0.26 1.49 ±1.70 21.85 ±20.82 26.9 83.3 90.9 11.5 12.5 18.2 10.0
M. furfur 0.28 ±0.36 2.29 ±2.89 11.92±12.94 26.9 79.2 100 15.4 29.2 18.2 26.7
M. slooﬃae 0.13 ±0.09 0.58 ±0.60 5.55 ±9.57 3.8 50.0 81.8 19.2 16.7 9.1 16.7
M. obtusa 0.16 ±0.13 1.15 ±1.35 4.17 ±2.92 11.5 62.5 90.9 19.2 16.7 18.2 10.0
a, Mean + standard deviation;
b, HS: healthy subject [22].
Table 2: Relationship between the number of species detected and total IgE antibody levels against Malassezia species in each case.
Severity group Number of species detected and total IgE antibody levels (IU/mL)
Less than three species Four or ﬁve species More than six species
Mild 1.27 +1.33 (13)a 4.33+ 7.00 (9) 8.62 +6.40 (4)
Moderate 8.75+ 8.41 (12) 43.44+ 20.27 (8) 49.58 +27.04 (4)
Severe 114.48 +89.27 (8) 102.38 (1) 248.20 +123.74 (2)
aMean + standard deviation. Number of sample examined is shown in parentheses.
of species detected in each patient was similar among the
three clinical severity groups (3.7 ± 1.6, 3.7 ± 1.6, and 3.5
± 1.4 species in mild, moderate, and severe AD cases, resp.).
The number of species detected in each severity group
was compared with the total IgE antibody levels against Ma-
lassezia species. As the number of detected species increased,
total level IgE antibody levels against Malassezia species also
increased (Table 2).
4. Discussion
In this study, we investigated the relationships between spe-
ciﬁc IgE levels and the colonization frequency of the eight
predominant Malassezia species and clinical severity in pa-
tients with HNAD to elucidate the factors correlated with
clinical severity. Some studies have reported that the fre-
quency of anti-Malassezia-speciﬁc IgE antibodies in serum
was higher in patients with HNAD than in those without.
However, the detection frequency of anti-Malassezia-speciﬁc
IgE antibodies in patients with HNAD was diﬀerent in each
report: 100% [14], 68% [23], 55% [24], 55% [15], and 35%
[13].
Several factors may explain this variance. Of them, the
antigen used might have a signiﬁcant inﬂuence on the fre-
quency of detection. These aforementioned studies had
prepared Malassezia antigens from M. furfur or M. sympodi-
alis to detect speciﬁc IgE antibodies from patients’ sera.
Unfortunately, these microorganisms are not the predom-
inant species on the skin of patients with AD. M. globosa
and M. restricta were detected in all patients, while M.
furfur and M. sympodialis were observed in 15.4–29.2%
and 54.5–61.5% of the patients, respectively. In addition to
detection frequency, colonization levels of M. globosa and
M. restricta accounted for greater than 90% of the entire
Malassezia microbiota [25]. Therefore, M. globosa and M.
restricta may play a role in exacerbating AD. Based on this
result, Kato et al. [19] quantiﬁed speciﬁc IgE against eight
Malassezia species, M. dermatitis, M. furfur, M. globosa, M.
obtusa, M. pachydermatitis, M. slooﬃae, M. sympodialis,a n d
M. restricta, in sera from patients with AD by enzyme-
linked immunosorbent assay (ELISA). The level of speciﬁc
IgE antibodies for M. restricta was greater than that against
other Malassezia species. Competitive ELISA inhibition tests
revealed that M. restricta contained species-speciﬁc as well as
shared antigens.
The colonization level of Malassezia in scale samples
from patients with AD also diﬀered according to clinical se-
verity. The extent of Malassezia colonization between pa-
tients with mild and moderate AD was similar. However, col-
onization in severe patients was two- to ﬁvefold higher than
thatofmildandmoderatepatients[26].Inaddition,thepro-
portions of the two predominant species, M. globosa and M.
restricta,diﬀeredaccordingtotheclinicalseverity.Inpatients
with mild and moderate AD, M. restricta predominated over
M. globosa, whereas the proportions of M. globosa and M.
restricta were almost identical in patients with severe AD.
AD severity had no eﬀect on Malassezia species diversity in
patients with 3.45–3.71 species colonizing the skin; however,
the number of species detected ranged from two to seven
of a total of eight. The number of species detected in each
case correlated with the total level of speciﬁc IgE antibodies
against Malassezia species in each severity group (Table 2).4 Journal of Allergy
Therefore, to elucidate the factors associated with the
clinical severity of AD, the relationships between speciﬁc IgE
levels and colonization levels with the eight most predomi-
nant Malassezia species should be investigated.
5. Conclusion
TheclinicalseverityofHNADwascorrelatedwithtotallevels
of IgE antibodies against Malassezia species and the number
of Malassezia species detected in each case.
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